TAS-114

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameTAS-114
Drug Alias NameTAS-114
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydropyrimidine dehydrogenase inhibitorsdUTP pyrophosphatase inhibitors
TargetsDihydropyrimidine dehydrogenasedUTP pyrophosphatase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTaiho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaiho Pharmaceutical Co LtdTaiho Oncology Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A